Standard and Interpretation
Guidelines for diagnosis and treatment of glucocorticoid-induced osteoporosis
He Jing, Li Fen, Huang Wenhui, Wang Liping, Zhang Xuewu, Zhao Yan, on behalf of Chinese Rheumatology Association
Published 2023-06-01
Cite as Chin J Intern Med, 2023, 62(6): 631-638. DOI: 10.3760/cma.j.cn112138-20221025-00787
Abstract
Glucocorticoid-induced osteoporosis (GIOP) is a skeletal disease characterized by decreased bone strength and increased fracture risk associated with long-term glucocorticoid use. GIOP is the most common secondary osteoporosis that critically affects the quality of life of patients. Currently, the incidence of GIOP in China remains high, with insufficient awareness and lack of prevention and treatment norms. Therefore, the Chinese Rheumatology Association has established this standard based on domestic and international experience, with the aim of raising awareness of prevention and treatment among clinicians, guiding the standardized diagnosis and treatment of this disease, and improving the overall prognosis of patients with GIOP.
Key words:
Glucocorticoids; Osteoporosis; Prevention; Treatment; Standard
Contributor Information
He Jing
Department of Rheumatology and Immunology, Peking University People′s Hospital, Beijing 100044, China
Li Fen
Department of Rheumatology and Immunology, the Second Xiangya Hospital of Central South University, Changsha 410011, China
Huang Wenhui
Department of Rheumatology and Immunology, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China
Wang Liping
Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou 730030, China
Zhang Xuewu
Department of Rheumatology and Immunology, Peking University People′s Hospital, Beijing 100044, China
Zhao Yan
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science &
Technology, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China
on behalf of Chinese Rheumatology Association
